The ZENMARx Medication Error Prevention Protocol is firmly grounded in procedures used by global health authorities to evaluate the safety of new trade name submissions.
Our process utilizes:
- Identification and Incorporation of Clinical Criteria
- Analysis of potential Look-alike / Sound-alike (LASA) similarity
- Use of Failure Mode and Effects Analysis (FMEA)
- International Phonetic and Orthographic Computer Analysis (POCA) screen
- Reliance upon a wide array of Practitioner Input
- Consideration of USAN & WHO Criteria for Non-Proprietary Names
- Seasoned Expert Panel Analysis
- Careful Assignment of Risk which considers potential “misbranding” aspects
- Detailed Report providing Actionable Data for Regulatory Submission
While no Safety Testing provider can guarantee a given name will receive regulatory approval, Zenmark guarantees our identification of risk is accurate and actionable.
The ZENMARx process has been successfully utilized in overcoming multiple initial regulatory rejections.